- Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry2017 | First Faculty of Medicine
- Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma2012 | First Faculty of Medicine
- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study2017 | First Faculty of Medicine
- Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy2017 | First Faculty of Medicine
- Alemtuzumab long-term immunologic effect Treg suppressor function increases up to 24 months2016 | First Faculty of Medicine
- Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings2017 | First Faculty of Medicine
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS2016 | First Faculty of Medicine
- Tolerability and Safety of the New Anti-Obesity Medications2014 | Third Faculty of Medicine